PPL 003

Drug Profile

PPL 003

Alternative Names: PPL-003

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Portage Biotech
  • Developer EyGen; Portage Biotech
  • Class Anti-inflammatories; Eye disorder therapies; Peptides; Recombinant fusion proteins
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders
  • No development reported Dry eyes; Uveitis

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Dry-eyes in USA (Topical, Drops)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Uveitis in USA (Topical, Drops)
  • 14 Dec 2016 Preclinical trials in Neurological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top